Selected announcements | China Gold International changed from profit to loss in Q1; Zhongtong Express's adjusted net profit increased 15.8% year-on-year
China Shenhua: Commercial coal production in April was 27.5 million tons, up 5.4% year on year; coal sales volume was 37 million tons, up 1.1% year on year; Ping An of China: the total premium income from the original insurance contracts of the four subsidiaries in the first 4 months was about 33.377 billion yuan, up 2.4% year on year.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
The market is picking up, and listed companies are pouring in medical and aesthetic institutions. Who will win the next “C-rank material”?
Catalyzed by various factors, the medical and aesthetic market recovered to a certain extent in the first quarter, while the performance of listed companies, whether midstream medical and aesthetic institutions or upstream producers, has steadily improved since this year.
德斯控股:2023年度報告
德斯控股:2023第三季度業績報告